Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 14Colorectal Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1PIK3CA-Mutated Cancers 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Cetuximab 5olaparib 3atezolizumab 3Injections 3fludarabine 2Trastuzumab 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2zimberelimab 1zansecimab 1tocilizumab 1taxane 1spartalizumab 1somatostatin receptor 2 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1lenvatinib 1ipatasertib 1inavolisib 1fludarabine phosphate 1entrectinib 1encorafenib 1durvalumab 1dapagliflozin 1cemiplimab 1brigimadlin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × inavolisib × 1 year × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡